BRPI0414553A - previsão do resultado de tratamento contra o cáncer de mama - Google Patents

previsão do resultado de tratamento contra o cáncer de mama

Info

Publication number
BRPI0414553A
BRPI0414553A BRPI0414553-4A BRPI0414553A BRPI0414553A BR PI0414553 A BRPI0414553 A BR PI0414553A BR PI0414553 A BRPI0414553 A BR PI0414553A BR PI0414553 A BRPI0414553 A BR PI0414553A
Authority
BR
Brazil
Prior art keywords
breast cancer
tamoxifen
response
prediction
cases
Prior art date
Application number
BRPI0414553-4A
Other languages
English (en)
Inventor
Xiao-Jun Ma
Mark G Erlander
Dennis C Sgroi
Edward Enright
Original Assignee
Arcturus Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/727,100 external-priority patent/US7504214B2/en
Priority claimed from US10/773,761 external-priority patent/US9856533B2/en
Application filed by Arcturus Bioscience Inc filed Critical Arcturus Bioscience Inc
Publication of BRPI0414553A publication Critical patent/BRPI0414553A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/40—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Primary Health Care (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

"PREVISãO DO RESULTADO DE TRATAMENTO CONTRA O CáNCER DE MAMA". Métodos e composições são providos para a identificação de assinaturas de expressão em casos de câncer de mama ER+, onde as assinaturas estão correlacionadas com a resposta, ou falta da mesma, ao tratamento com tamoxifeno ou outro agente antiestrogênico contra câncer de mama. Os perfis de assinatura são identificados com base na amostragem de amostras de tecido de mama de referência a partir de casos independentes de câncer de mama e provêem um conjunto confiável de critérios moleculares para prever a eficácia de tratamento de um indivíduo com câncer de mama com tamoxifeno ou outro agente antiestrogênico contra câncer de marna. Métodos adicionais e composições são providos para prever a resposta a tamoxifeno ou outro agente antiestrogênico contra câncer de mama em casos de câncer de mama por uso de biomarcadores múltiplos. Dois biomarcadores mostram uma expressão aumentada correlacionada com a resposta a tamoxifeno enquanto dois outros biomarcadores mostram expressão diminuída correlacionada com a resposta a tamoxifeno.
BRPI0414553-4A 2003-09-19 2004-09-17 previsão do resultado de tratamento contra o cáncer de mama BRPI0414553A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US50408703P 2003-09-19 2003-09-19
US10/727,100 US7504214B2 (en) 2003-09-19 2003-12-02 Predicting outcome with tamoxifen in breast cancer
US10/773,761 US9856533B2 (en) 2003-09-19 2004-02-06 Predicting breast cancer treatment outcome
US54719904P 2004-02-23 2004-02-23
PCT/US2004/030789 WO2005028681A1 (en) 2003-09-19 2004-09-17 Predicting breast cancer treatment outcome

Publications (1)

Publication Number Publication Date
BRPI0414553A true BRPI0414553A (pt) 2006-11-07

Family

ID=34382172

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414553-4A BRPI0414553A (pt) 2003-09-19 2004-09-17 previsão do resultado de tratamento contra o cáncer de mama

Country Status (7)

Country Link
US (1) US20060154267A1 (pt)
EP (1) EP1670946B1 (pt)
JP (1) JP2007505630A (pt)
AU (1) AU2004274973A1 (pt)
BR (1) BRPI0414553A (pt)
CA (1) CA2539107A1 (pt)
WO (1) WO2005028681A1 (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030198972A1 (en) 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
US9856533B2 (en) 2003-09-19 2018-01-02 Biotheranostics, Inc. Predicting breast cancer treatment outcome
US8540968B2 (en) 2004-03-02 2013-09-24 Cellectar, Inc. Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
ATE437657T1 (de) 2004-03-02 2009-08-15 Cellectar Inc Phospholipid-analoga für die behandlung von krebs
WO2006103442A2 (en) * 2005-04-01 2006-10-05 Ncc Technology Ventures Pte. Ltd. Materials and methods relating to breast cancer classification
US20070134688A1 (en) * 2005-09-09 2007-06-14 The Board Of Regents Of The University Of Texas System Calculated index of genomic expression of estrogen receptor (er) and er-related genes
CN100457922C (zh) * 2005-10-20 2009-02-04 康哲医药研究(深圳)有限公司 检测酪丝亮肽抗肝癌效果的方法及所用试剂盒与基因芯片
US20090326333A1 (en) * 2005-12-09 2009-12-31 Goetz Matthew P Assessing outcomes for breast cancer patients
WO2007095330A2 (en) 2006-02-15 2007-08-23 Hologic Inc Breast biopsy and needle localization using tomosynthesis systems
JP2007267700A (ja) * 2006-03-31 2007-10-18 Kochi Univ Ｈｏｘｂ１３遺伝子のメチル化を指標とする腎細胞癌を含む悪性腫瘍の判定方法
WO2008143669A1 (en) * 2006-05-18 2008-11-27 Mayo Foundation For Medical Education And Research Assessing outcomes for breast cancer patients
EP1873258A1 (en) * 2006-06-26 2008-01-02 Universitätsklinikum Hamburg-Eppendorf Detection of ESR1 amplification in breast cancer
WO2008049953A1 (es) 2006-10-23 2008-05-02 Neocodex, S.L. Método de pronóstico y/o diagnóstico in vitro de hipersensibilidad a estrógenos o a sustancias con actividad estrogénica
WO2008133493A1 (en) * 2007-04-27 2008-11-06 Erasmus University Medical Center Rotterdam Prediction of responsiveness to anti-estrogen treatment in breast cancer
JP2010538609A (ja) * 2007-09-06 2010-12-16 バイオセラノスティクス，インコーポレイティド 腫瘍グレード分類と癌の予後診断
WO2009067611A1 (en) * 2007-11-20 2009-05-28 University Of South Florida Seven gene breast cancer predictor
US10295540B1 (en) * 2009-02-13 2019-05-21 Cancer Genetics, Inc. Systems and methods for phenotypic classification using biological samples of different sample types
JP6092624B2 (ja) 2009-06-12 2017-03-08 セレクター，インコーポレイティド 癌の治療並びに癌幹細胞の造影および検出のためのエーテルおよびアルキルリン脂質化合物
GB0916124D0 (en) 2009-09-15 2009-10-28 Univ Cardiff Method and kit for the classification and prognosis of wounds
EP2485651B1 (en) 2009-10-08 2020-12-23 Hologic, Inc. Needle breast biopsy system
CA2795436C (en) * 2010-04-22 2017-12-05 Toray Industries, Inc. Method for preparing arna and method for analysis of gene expression
CN103998064A (zh) * 2010-12-09 2014-08-20 生物诊断治疗公司 治疗后的乳腺癌预后
GB201021182D0 (en) 2010-12-14 2011-01-26 Univ Cardiff Methdo and kit for the classification and prognosis of chronic wounds
US8914238B2 (en) * 2011-01-28 2014-12-16 Biodesix, Inc. Method for predicting breast cancer patient response to endocrine therapy
GB201103898D0 (en) 2011-03-08 2011-04-20 Univ Cardiff Molecular targets for healing or treating wounds
CA2829349C (en) 2011-03-08 2021-02-09 Hologic, Inc. System and method for dual energy and/or contrast enhanced breast imaging for screening, diagnosis and biopsy
AU2012332481B2 (en) * 2011-11-04 2017-01-19 Invivis Sas Assay for predictive biomarkers of anti-estrogen efficacy
JP2014534042A (ja) 2011-11-27 2014-12-18 ホロジック, インコーポレイテッドHologic, Inc. マンモグラフィーおよび／またはトモシンセシス画像データを使用して２ｄ画像を生成するためのシステムおよび方法
US9805507B2 (en) 2012-02-13 2017-10-31 Hologic, Inc System and method for navigating a tomosynthesis stack using synthesized image data
EP2967473B1 (en) 2013-03-15 2020-02-19 Hologic, Inc. System and method for navigating a tomosynthesis stack including automatic focusing
JP6388347B2 (ja) 2013-03-15 2018-09-12 ホロジック, インコーポレイテッドHologic, Inc. 腹臥位におけるトモシンセシス誘導生検
BR112016005225B1 (pt) 2013-09-11 2023-11-14 Bio Theranostics, Inc Métodos para avaliar câncer de mama em um indivíduo
JP6506769B2 (ja) 2014-02-28 2019-04-24 ホロジック, インコーポレイテッドHologic, Inc. トモシンセシス画像スラブを生成し表示するためのシステムおよび方法
WO2016207986A1 (ja) * 2015-06-24 2016-12-29 株式会社日立製作所 検査システム、検査装置、及び検査方法
WO2017083675A1 (en) 2015-11-13 2017-05-18 Biotheranostics, Inc. Integration of tumor characteristics with breast cancer index
CN109072481B (zh) 2015-12-07 2022-03-18 安大略省癌症研究所 早期乳腺癌内分泌治疗后剩余风险的基因特征
CN110621233B (zh) 2017-03-30 2023-12-12 豪洛捷公司 用于处理乳房组织图像数据的方法
EP3600047A1 (en) 2017-03-30 2020-02-05 Hologic, Inc. System and method for hierarchical multi-level feature image synthesis and representation
KR102397337B1 (ko) * 2017-05-29 2022-05-12 출라폰 파운데이션 간세포 암종(hcc) 또는 담관암종(cca)을 갖는 개체의 생존결과를 예측하는 방법
JP7571006B2 (ja) * 2018-08-17 2024-10-22 ジェネンテック， インコーポレイテッド 乳がんの処置のための診断的および治療的方法
WO2020068851A1 (en) * 2018-09-24 2020-04-02 Hologic, Inc. Breast mapping and abnormality localization
US12505645B2 (en) 2020-03-27 2025-12-23 Hologic, Inc. Systems and methods for correlating regions of interest in multiple imaging modalities
JP7671776B2 (ja) 2020-03-27 2025-05-02 ホロジック， インコーポレイテッド 複数の画像化モダリティにおける関心対象領域を識別するシステム及び方法
US12254586B2 (en) 2021-10-25 2025-03-18 Hologic, Inc. Auto-focus tool for multimodality image review
CN118318247A (zh) 2021-11-29 2024-07-09 豪洛捷公司 用于将感兴趣的对象相关的系统和方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1410011B1 (en) * 2001-06-18 2011-03-23 Rosetta Inpharmatics LLC Diagnosis and prognosis of breast cancer patients
US7622260B2 (en) * 2001-09-05 2009-11-24 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
US7504214B2 (en) * 2003-09-19 2009-03-17 Biotheranostics, Inc. Predicting outcome with tamoxifen in breast cancer

Also Published As

Publication number Publication date
CA2539107A1 (en) 2005-03-31
EP1670946A1 (en) 2006-06-21
WO2005028681A1 (en) 2005-03-31
JP2007505630A (ja) 2007-03-15
AU2004274973A1 (en) 2005-03-31
EP1670946B1 (en) 2012-11-07
US20060154267A1 (en) 2006-07-13

Similar Documents

Publication Publication Date Title
BRPI0414553A (pt) previsão do resultado de tratamento contra o cáncer de mama
Huang et al. Epigenetics in breast cancer: what's new?
BR112012030625A2 (pt) uso de inibidores de tirosina quinase de bruton (btk)
Ying et al. Epigenetic repression of regulator of G‐protein signaling 2 by ubiquitin‐like with PHD and ring‐finger domain 1 promotes bladder cancer progression
NZ593225A (en) Gene expression markers (CMYC and Ki-67) for colorectal cancer prognosis
WO2004111273A3 (en) Gene expression markers for response to egfr inhibitor drugs
EA200600689A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов raf киназы
BRPI0411743A (pt) método e composições para tratar doenças relacionadas a amilóides
TW200512298A (en) Method of diagnosing breast cancer
IL177346A0 (en) Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
BRPI0416268A (pt) composições de delta-9-thc e métodos para o tratamento de sintomas associados à esclerose múltipla
CU20080027A7 (es) Bencimidazoles sustituidos como inhibidores de cinasa
BRPI1013688A8 (pt) Proteínas de ligação de il-17.
BRPI0701433A (pt) uso de uma composição cosmética, processo para melhorar a cor das fibras queratìnicas tingidas artificialmente, processo de coloração e agente de coloração multicomponente ou kit
BRPI1007048A2 (pt) método e kit para correlacionar os níveis relativos da quantidade de pelo menos um de her-2 ou homodímeros de her-2 em uma amostra biológica de um indivíduo, e , método para prognosticar se um indivíduo com câncer e que é tratado com um agente que atua em her-2 é provável ter um evento significante.
BRPI0417903A (pt) método de melhorar a detecção de sinal de um componente de parede celular de células
WO2006074367A3 (en) Method of predicting and reducing risk of metastasis of breast cancer to lung
WO2005040421A3 (en) Prognostic and diagnostic markers for cell proliferative disorders of the breast tissues
MX2009005941A (es) Ensayos de diagnostico complementario para terapia de cancer.
BRPI0718469A2 (pt) Uso de um antagonista de interleucina 1 (il-1), método para tratar, inibir, ou melhorar pseudogota, uso de um ou mais agentes terapêuticos, e, produto.
ATE496635T1 (de) Verfahren und zusammensetzungen zur hemmung, prävention oder verringerung des tumorzellwachstums bei patienten, die gegen die antineoplastischen wirkungen einer antiöstrogen- therapie resistent sind
Cheng et al. Interplay between menin and Dnmt1 reversibly regulates pancreatic cancer cell growth downstream of the Hedgehog signaling pathway
CL2007002388A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas.
MX2007008136A (es) Metodo para invertir la resistencia multiple en celulas animales.
BR0308634A (pt) Uso de um adenovìrus, e, composição

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2112 DE 28/06/2011.